Atomoxetine, a selective norepinephrine (NE) reuptake inhibitor, was approved for attention
deficit/hyperactivity disorder (ADHD) treatment in children, adolescents and adults. We …

Neuropsychiatric disorders are multifactorial disorders with diverse aetiological factors.
Identifying treatment targets is challenging because the diseases are resulting from …

Attention Deficit/Hyperactivity Disorder is the most prevalent neurodevelopmental disorder
worldwide. Choice treatment includes psychostimulants, but parents tend to be reluctant to …

Objectives This study investigates the impact of various physical activity (PA) types on
executive functions (EFs) in children and adolescents. Design A systematic review and …

Methylphenidate (MPH) is the treatment of first choice for developmental ADHD. To date, no
reliable method to predict how patients will respond to MPH exists and conflicting results are …

Abstract Background and Objective Methylphenidate (MPH) and atomoxetine (ATX) are the
most common medications used to treat attention-deficit hyperactivity disorder (ADHD) in …

Based on core symptoms of inattention and deficient impulse control, and the identification
of effective pharmacotherapies such as amphetamine (AMP; Adderall®), methylphenidate …

Objective: To characterize executive function in adolescents with generalized anxiety
disorder (GAD) and its relationship to treatment. Methods: Using data from a double-blind …

Attention-deficit/hyperactivity disorder (ADHD) is comprised of two behavioral clusters of
symptoms, inattention and hyperactivity/impulsivity. Numerous studies have attempted to …

Objective: Methylphenidate is effective in reducing the clinical symptoms of patients with
attention-deficit/hyperactivity disorder (ADHD). ORADUR®-methylphenidate is a new …